Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Immunomodulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation with treatment response.To describe the frequency and spectrum of cutaneous AEs linked with pembrolizumab and their possible correlation with treatment response.A...